Form 4: Novavax Executive John Trizzino Reports Acquisition of 144,000 Restricted Stock Units
SEC Form 4 Filing
EVP, CCO and CBO of Novavax, John Trizzino, reports the acquisition of 144,000 restricted stock units on March 1, 2024.
Summary
- John Trizzino, EVP, CCO and CBO of Novavax, filed a Form 4 on March 26, 2024, reporting changes in beneficial ownership.
- On March 1, 2024, Trizzino acquired 144,000 Restricted Stock Units (RSUs).
- Each RSU represents a contingent right to receive one share of Novavax's common stock.
- The RSUs vest in three equal installments on the first three anniversaries of the grant date (March 1, 2024), contingent upon continued employment.
Sentiment
Score: 5
Explanation: This is a neutral event, reflecting standard executive compensation practices.
Future Outlook
The vesting of the RSUs is contingent upon continued employment with Novavax.
Industry Context
This filing is a routine disclosure related to executive compensation and equity grants, common in publicly traded companies.
Stakeholder Impact
- The vesting of RSUs may slightly dilute existing shareholders' equity over time.
Key Dates
| Date | Description |
|---|---|
| 03/01/2024 | Date of transaction: Acquisition of 144,000 Restricted Stock Units. |
| 03/01/2025 | First vesting date for one-third of the RSUs. |
| 03/26/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.